Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling

Oncogene

Volumn 35, Issue 17, 2016, Pages 2166-2177

  Kruiswijk, F ^a   Hasenfuss, S C ^a   Sivapatham, R ^b   Baar, M P ^a   Putavet, D ^a   Naipal, K A T ^a   Van Den Broek, N J F ^a   Kruit, W ^a   Van Der Spek, P J ^a   Van Gent, D C ^a   Brenkman, A B ^a,c   Campisi, J ^b,d   Burgering, B M T ^a   Hoeijmakers, J H J ^a   De Keizer, P L J ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MELANIN; PEPTIDYLPROLYL ISOMERASE PIN1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; VEMURAFENIB; BRAF PROTEIN, HUMAN; FORKHEAD BOX PROTEIN M1; FOXM1 PROTEIN, HUMAN; INDOLE DERIVATIVE; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE; PIN1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CELL CYCLE PROGRESSION; CELL PERMEABILIZATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA CELL; MELANOMA CELL LINE; METASTATIC MELANOMA; ONCOGENE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; FORKHEAD BOX PROTEIN M1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MELANOMA; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84939442718     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.282     Document Type: Article

References (48)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
2. Damsky WE, Theodosakis N, Bosenberg M. Melanoma metastasis: new concepts and evolving paradigms. Oncogene 2014; 33: 2413-2422.
3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
5. Solit D, Sawyers CL. Drug discovery: how melanomas bypass new therapy. Nature 2010; 468: 902-903.
6. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
8. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
9. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29: 3085-3096.
10. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011; 19: 11-15.
11. Ma RY, Tong TH, Cheung AM, Tsang AC, Leung WY, Yao KM. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J Cell Sci 2005; 118: 795-806.
12. Korver W, Roose J, Clevers H. The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic Acids Res 1997; 25: 1715-1719.
13. Li X, Qiu W, Liu B, Yao R, Liu S, Yao Y et al. Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel. J Transl Med 2013; 11: 204.
14. Zhang N, Wu X, Yang L, Xiao F, Zhang H, Zhou A et al. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res 2012; 18: 5961-5971.
15. Reed JA, Loganzo Jr F, Shea CR, Walker GJ, Flores JF, Glendening JM et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995; 55: 2713-2718.
16. Down CF, Millour J, Lam EW, Watson RJ. Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb. Biochim Biophys Acta 2012; 1819: 855-862.
17. Halasi M, Gartel AL. A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle 2009; 8: 1966-1967.
18. Verdecia MA, Bowman ME, Lu KP, Hunter T, Noel JP. Structural basis for phosphoserine-proline recognition by group IV WW domains. Nat Struct Biol 2000; 7: 639-643.
19. Lu KP, Zhou XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 2007; 8: 904-916.
20. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7: 126-136.
21. Alvarez B, Martinez A, Burgering BM, Carrera AC. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 2001; 413: 744-747.
22. Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 2014; 25: 638-651.
23. Dhomen N, Reis-Filho JS, da Rocha DS, Hayward R, Savage K, Delmas V et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009; 15: 294-303.
24. Jones AT, Sayers EJ. Cell entry of cell penetrating peptides: tales of tails wagging dogs. J Control Release 2012; 161: 582-591.
25. Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M et al. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res 2014; 20: 4816-4826.
26. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001; 50: 77-82.
27. Alcala AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res 2012; 18: 33-39.
28. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251-255.
29. Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res 2013; 73: 7043-7055.
30. Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers. Nature 2013; 501: 232-236.
31. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014; 4: 61-68.
32. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
33. Raychaudhuri P, Park HJ. FoxM1: a master regulator of tumor metastasis. Cancer Res 2011; 71: 4329-4333.
34. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011; 20: 620-634.
35. Gusarova GA, Wang IC, Major ML, Kalinichenko VV, Ackerson T, Petrovic V et al. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest 2007; 117: 99-111.
36. Damsky Jr WE, Bosenberg M. Mouse melanoma models and cell lines. Pigment Cell Melanoma Res 2010; 23: 853-859.
37. Walker GJ, Soyer HP, Terzian T, Box NF. Modelling melanoma in mice. Pigment Cell Melanoma Res 2011; 24: 1158-1176.
38. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 2009; 23: 529-545 ix.
39. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr WE et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41: 544-552.
40. de Keizer PL, Packer LM, Szypowska AA, Riedl-Polderman PE, van den Broek NJ, de Bruin A et al. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. Cancer Res 2010; 70: 8526-8536.
41. Brenkman AB, de Keizer PL, van den Broek NJ, van der GP, van Diest PJ, van der HA et al. The peptidyl-isomerase Pin1 regulates p27kip1 expression through inhibition of Forkhead box O tumor suppressors. Cancer Res 2008; 68: 7597-7605.
42. Geurts-Giele WR, Leenen CH, Dubbink HJ, Meijssen IC, Post E, Sleddens HF et al. Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers. J Pathol 2014; 234: 548-559.
43. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11: 7234-7242.
44. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008; 1: 13.
45. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP et al. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 2008; 6: 760-769.
46. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007; 447: 966-971.
47. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/mela-noma in situ and advanced-stage melanomas. Cancer Biol Ther 2005; 4: 1018-1029.
48. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 2009; 106: 20429-20434.